Миропристон

Quick links

Choose a section

Quick links to important sections

Advertisements

Миропристон

Selected form

Advertisements
Advertisements

Treatment option: Pregnancy

Advertisements

Overview of Миропристон

Property Description
Active ingredient Mifepristone (INN)
Form Tablets (for oral administration)
Pharmacological class Antiprogestin (Progesterone Receptor Antagonist)
General purpose Management of hormone-dependent conditions
Origin Synthetic compound

Миропристон: Definition and Pharmacological Classification

Миропристон is a prescription-only medication whose active component is the international non-proprietary name (INN) Mifepristone. This drug belongs to the pharmacological class of antiprogestins, structurally classified as a synthetic steroidal derivative. The primary mode of action defines it as a potent Progesterone receptor antagonist. This action involves blocking progesterone receptors, which is fundamental to the drug's therapeutic effect. This anti-hormonal mechanism is clinically recognized for achieving specific outcomes in reproductive health. The drug is categorized as an essential medicine for healthcare systems.

Composition, Origin, and Dosage Form

The core component, Mifepristone, is a chemically distinct synthetic compound that was historically identified by its developmental code name, RU-486. The drug is a single product presented for oral administration in the form of tablets. This form is achieved by combining the active Mifepristone with necessary solid pharmaceutical excipients to ensure stability and consistent systemic delivery. While other brands with the same active ingredient exist, Миропристон differentiates itself as a particular formulation of this essential medicine, maintaining the standardized characteristics required by pharmacopoeial guidelines.

Core Antihormonal Purpose

The general therapeutic purpose of Миропристон stems from its ability to induce powerful progesterone receptor blockade within the body's cells. This fundamental antihormonal action is utilized in clinical settings to achieve specific, hormone-dependent physiological outcomes in women of reproductive age. Furthermore, the compound exhibits a secondary activity as a Glucocorticoid receptor antagonist. This dual mechanism involves binding to glucocorticoid receptors, extending the compound's influence beyond progesterone. This pharmacological breadth allows for its use in addressing certain endocrine disorders through the suppression of cortisol action.

Regulatory References

  1. NIH/NLM Drug Record for Mifepristone
  2. NIH/NLM Drug Record
  3. WHO Essential Medicines List (21st edition, 2019)
  4. WHO Essential Medicines List
Advertisements

What side effects are possible with Миропристон?

Possible side effects and safety information

The safety profile of Миропристон (Mifepristone) is strictly defined by government regulatory documents, which formally classify adverse reactions by frequency and the body system affected. These classifications structure the understanding of the medicine’s risk profile, distinguishing between commonly expected effects and rare, serious outcomes.

Frequency-Classified Adverse Reactions

Adverse reactions are documented according to their frequency in clinical data, based on regulatory standards:

  • Very Common (≥ 10%): Nausea, Vomiting, Diarrhea, Abdominal pain/cramping, Headache, and Fatigue/Weakness.
  • Common (1% to < 10%): Back pain, Dizziness, and Uterine Bleeding (which can be heavy or prolonged in certain contexts).
  • Rare (< 0.1%): Serious adverse events such as Myocardial Infarction, Uterine Rupture, and severe infections, including fatal septic shock, are documented in official safety warnings.

System-Organ Class and Safety Constraints

Side effects are primarily observed in the Gastrointestinal and Reproductive Systems and Breast Disorders categories. The drug's mechanism also necessitates attention to Endocrine Disorders, particularly adrenal function during prolonged use in specific indications.

Safety limitations are defined by regulatory agencies. Use is formally not recommended in individuals with severe hepatic or renal impairment due to a lack of sufficient safety data. Furthermore, the medicine is contraindicated for use in patients with Chronic Adrenal Failure, confirmed or suspected Ectopic Pregnancy, or uncontrolled coagulopathy, as specified in official labeling. These constraints establish the formal boundaries for the drug's safe application.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Миропристон (Mifepristone) describes specific manifestations and conditions that require urgent medical attention. Acute high-dose exposure (ge 4.5 mg/kg) is documented to result in a compensatory elevation of ACTH and cortisol due to the drug’s anti-glucocorticoid activity. While no specific antidote is known, management involves symptomatic and supportive treatment; some regulatory documents note that specialized treatment may include the administration of dexamethasone for acute anti-glucocorticoid intoxication.

Life-Threatening Manifestations

Severe outcomes reported in regulatory documents include rare instances of fatal septic shock, severe bacterial infection, and complications requiring intervention such as uterine rupture. You must seek immediate medical attention or go to the nearest hospital emergency room if you experience:

  • Prolonged heavy vaginal bleeding, defined as soaking through two thick full-size sanitary pads per hour for two consecutive hours.
  • Sustained fever of 100.4 F (or higher) lasting more than four hours.
  • Severe abdominal pain or syncope (fainting).

Prompt medical or surgical intervention, including blood transfusions, may be necessary to manage severe hemorrhage or other critical complications.

Advertisements

Therapeutic Uses of Миропристон

The medication is considered relevant for use across domains where additional symptomatic support is needed. The drug is applied in addressing conditions that involve noticeable physiological strain.

Endocrine Control of Metabolic Dysfunction

This therapeutic domain is applied in clinical settings that involve acute or unstable symptom patterns for patients with severe endocrine conditions. It is relevant for easing symptoms related to systemic imbalance, particularly high blood sugar associated with these conditions. This may assist with maintaining functional stability during periods of increased physiological stress.

Medical Management in Early Reproductive Health

Миропристон is commonly used to help with the medical management of specific reproductive statuses, such as an early intrauterine pregnancy or managing early pregnancy loss. It supports the patient during difficult episodes by easing distress and is applied in contexts where supportive symptom management is appropriate.

Quick Fact: Relief for Complex Symptom Clusters

Миропристон is relevant for easing symptoms related to systemic imbalance, particularly high blood sugar, and assists with managing physical discomfort in gynecological pathology. This provides support that helps ease the overall symptom burden.

Regulatory References

  1. NIH MedlinePlus Drug Information overview
Advertisements

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Миропристон

The eligibility for Миропристон is strictly defined by regulatory documents and varies based on the approved use (e.g., specific reproductive health management or endocrine control). Official labeling categorizes patient groups who must not use the medicine, as well as those who require special caution.

Populations Who Must Not Use (Contraindicated)

  • Ectopic Pregnancy: Contraindicated in confirmed or suspected ectopic pregnancy, as the treatment is ineffective for this condition.
  • Adrenal Function: Individuals with chronic adrenal failure or those on concurrent long-term corticosteroid therapy must not use the medicine.
  • Bleeding Risk: Patients with hemorrhagic disorders or those currently taking anticoagulant therapy are prohibited due to the risk of heavy bleeding.
  • Other Conditions: Contraindicated in patients with inherited porphyrias, a known history of allergy to the drug or its components, or if an Intrauterine Device (IUD) is currently in place (it must be removed prior to use).

Restricted and Age-Specific Use

  • Organ Function: For specific indications, use is restricted by organ health; a maximum dose limitation applies to patients with mild-to-moderate hepatic or renal impairment. Use is not recommended in cases of severe hepatic impairment.
  • Age Groups: Safety and effectiveness have not been established in pediatric patients. There is no specific information available regarding the relationship of age to the drug’s effects in geriatric patients.
  • Pregnancy/Lactation: The medicine is contraindicated if pregnancy occurs while the patient is being treated for conditions like Cushing’s syndrome. Breastfeeding is avoided during long-term therapy.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Mifepristone (Миропристон) is structured primarily by pharmacokinetic interactions involving Cytochrome P450 enzymes, especially CYP3A4.

Documented Interaction Restrictions

Co-administration with strong CYP3A4 inducers (such as Rifampin, Phenytoin, or Carbamazepine) is contraindicated because regulatory documents state they significantly reduce Mifepristone's systemic exposure, which can reduce its effect. Conversely, strong CYP3A4 inhibitors (such as Ketoconazole or Ritonavir) are documented to significantly increase Mifepristone's plasma concentration. Furthermore, Mifepristone itself is an inhibitor of CYP3A4, CYP2C8/2C9, and CYP2B6, necessitating that co-administered drugs that are substrates of these enzymes and have a narrow therapeutic range (e.g., Cyclosporine, Pimozide) are also contraindicated.

Pharmacodynamic and Substance Restrictions

Due to Mifepristone's documented antiglucocorticoid activity, co-administration with systemic corticosteroids used for life-sustaining purposes is contraindicated as it may negate their effect. Regarding consumption, the official label restricts use with Grapefruit juice and the herbal product St. John’s Wort, as both are documented to alter Mifepristone blood levels. Finally, a mandatory regulatory timing-based rule requires administering Misoprostol within a specific 24 to 48-hour window following Mifepristone.

Advertisements

Mechanism of Action

The core action of Миропристон (Mifepristone) is defined by its high-affinity, dual-action mechanism targeting steroid hormone receptors, establishing a sequence of events from the molecular level to tissue-wide physiological change.

Primary Mechanism: Progesterone Receptor Antagonism

This mechanism involves the drug acting as a high-affinity competitive antagonist at the Progesterone Receptor ( PR). By occupying the PR, the drug prevents endogenous progesterone from binding and initiating gene transcription necessary for the maintenance of the uterine lining. This molecular blockade arrests the normal decidual supportive process, resulting in the structural collapse and shedding of the lining tissue.


Secondary Mechanisms: Uterine Modulation and Glucocorticoid Blockade

The inhibition of progesterone signaling causes the myometrium (uterine muscle) to become significantly more sensitive to natural mediators like prostaglandins. This prepares the tissue for augmented smooth muscle contractions and promotes the softening and increased compliance of the cervix through connective tissue remodeling. Additionally, Миропристон acts as a competitive antagonist at the Glucocorticoid Receptor ( GR), disrupting the HPA axis and leading to the functional suppression of cortisol signaling, thus influencing the body's cortisol regulatory axis.

Advertisements

Dosage and Administration Information

How to use Миропристон

The administration of Миропристон (Mifepristone) follows two distinct protocols, each defining specific routes, doses, and timing.

Fixed-Dose Regimen (Reproductive Health)

The administration method is a sequential process. A single dose of 200 mg of Mifepristone is taken orally on Day 1. This is followed 24 to 48 hours later by 800 micrograms (mcg) of the concurrent agent, misoprostol, administered via the buccal route (placed between the cheek and gum). The total course includes a follow-up assessment with the provider 7 to 14 days after the initial Mifepristone dose.

Titrated Daily Regimen (Endocrine Control)

This protocol involves once-daily administration for long-term management. The initial starting dose is 300 mg and is taken with a meal. Tablets are swallowed whole and are not split, crushed, or chewed. The dosage is adjusted in 300 mg increments no more frequently than once every two to four weeks, up to a maximum daily dose of 1200 mg. For patients with renal impairment or mild-to-moderate hepatic impairment, the maximum dose is limited to 600 mg daily.

Advertisements

Recent Clinical Evidence

The research evidence for Миропристон is derived from distinct lines of investigation, including randomized controlled trials (RCTs), systematic reviews, and multicentre clinical studies.

Evidence in Reproductive Health

Large RCTs and meta-analyses examined the medicine for early reproductive health management, including early pregnancy loss. Researchers monitored the rate of complete management and the need for subsequent procedures. Studies frequently compared the combination of this medicine with a second agent against the second agent alone. The measured patterns in the primary outcome were observed to vary with gestational age, and these short-term findings are supported by studies assessed as having high certainty.

Evidence in Endocrine and Gynecological Support

Separate open-label trials have examined the medicine in adult patients with severe endocrine conditions, tracking changes in metabolic biomarkers and composite symptom scores (Global Clinical Response or GCR). Furthermore, research explores its use in diverse gynecological conditions such as uterine leiomyomas (fibroids) and later-stage reproductive management. In these latter areas, evidence quality varies, with many studies characterized by small sample sizes and limited comparative data.

Research Gaps and Duration

Follow-up durations are generally limited, meaning the durability of the observed effects is not well characterized beyond the short term (e.g., beyond 24 weeks for endocrine studies or two weeks for reproductive health studies). Data for special populations, such as children or older adults, remain insufficient, and research is ongoing to clarify key uncertainties.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Миропристон (FAQ)


Q: Can Миропристон be taken with common pain relievers?

Regulatory documents state that caution should be used with aspirin due to potential bleeding concerns. Official product information emphasizes specific enzyme interactions, such as those related to the CYP3A4 enzyme system.


Q: How quickly does Миропристон start to work?

For its use in reproductive health management, the major physiological effects are generally understood to begin after the second medication (misoprostol) is administered. The product label indicates that the process is often completed within 2 to 24 hours following the administration of the second medication.


Q: Are there any long-term side effects that have been noted with Миропристон?

Regulatory agencies continue to monitor the medicine's safety after approval through post-marketing surveillance programs. Periodic reviews by regulatory authorities continue to monitor post-marketing data and have not identified new safety concerns within the scope of review. Official research evidence currently has limitations regarding the long-term durability of observed effects.


Q: Do older adults react differently to Миропристон?

Official documents state that safety and effectiveness have not been specifically established for geriatric patients. No dedicated information is available regarding how the relationship of age may influence the drug’s effects in this population.


Q: How does Миропристон interact with hormonal birth control?

Official product information states that hormonal contraceptives are not recommended for concurrent use with Миропристон. Regulatory documents suggest using a non-hormonal, medically acceptable method to prevent pregnancy during treatment and for one month after treatment is stopped.


Q: Is the research on Миропристон considered conclusive?

Research evidence varies depending on the medical use. Large, high-certainty studies support its use in early reproductive health management, but evidence for other uses is sometimes characterized by varying quality. Research gaps remain, particularly regarding the long-term durability of observed effects and use in special populations.


Q: What are the reported success rates of Миропристон in clinical trials?

Clinical studies in reproductive health management track the rate of complete management as a key metric. Official reports on these studies indicate the drug's effectiveness, with reported success rates in specific clinical trials falling within a defined range.


Q: Can men use Миропристон?

Yes, the active ingredient in Миропристон is indicated for use in adult patients (including men) to control hyperglycemia secondary to hypercortisolism in Cushing’s syndrome. This use requires patients to meet specific criteria related to diabetes or glucose intolerance.


Q: What should I do if I forget to take a dose of Миропристон?

Regulatory guidance states that a person should contact their healthcare provider immediately for instructions concerning a missed dose. This ensures appropriate guidance is provided based on the specific regimen and time elapsed.


Q: Are there different strengths or types of Миропристон available?

The active ingredient (Mifepristone) is available in different strengths, which are used for different approved indications. For example, 200 mg tablets are used for reproductive health, and 300 mg tablets are used in the management of Cushing’s syndrome.


Q: How is the safety of Миропристон monitored after it is released?

Regulatory authorities monitor the safety of the medicine after approval through dedicated post-marketing surveillance programs. These programs are designed to collect and review reports of adverse events experienced by patients over time.


Q: Do any common herbs interfere with Миропристон?

The official product label specifically restricts use with the herbal product St. John’s Wort and Grapefruit juice because both are documented to alter the drug’s blood levels. No other specific herbs are universally restricted or named in the core regulatory documents regarding blood level alterations.


Q: Can Миропристон cause changes to my menstrual cycle?

Due to the drug's anti-hormonal mechanism of action, regulatory documents note potential effects such as changes to the uterine lining. Adverse events include vaginal bleeding, which can be heavy or prolonged in certain contexts, and endometrial thickening.


Q: Why are certain people ineligible to use Миропристон?

Ineligibility is based on specific health conditions that regulatory documents state present a risk of serious adverse outcomes. For example, individuals with chronic adrenal failure are contraindicated due to the drug's antiglucocorticoid activity, and those with bleeding risks are excluded due to the potential for heavy uterine bleeding.


Q: Does alcohol change how Миропристон works?

Official regulatory drug interaction sections do not report a specific interaction between alcohol (ethanol) and Миропристон.

Advertisements

How should Миропристон be stored and disposed of?

How to Store and Dispose of Mifepristone

Mifepristone tablets must be stored according to regulatory requirements to maintain product stability and safety. The medication requires storage at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The product must be protected from excess heat and moisture, and therefore should not be stored in high-humidity areas like the bathroom.

Packaging and Safety

For stability, the tablets must remain in the original container and the container must be tightly closed. It is a mandatory requirement to store the medication out of the sight and reach of children, utilizing a safe, secured location and locked safety caps.

Disposal Instructions

Official guidance for discarding unused or expired Mifepristone directs patients to consult their healthcare provider or pharmacist for instructions on safe disposal methods that comply with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Миропристон found in:

A-Z Index: